Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination Setty M.
Increased blood-brain barrier (BBB) disruption can be found in patients with neuromyelitis optica (NMO); however, its clinical implication and association with disability at acute attack remains obscure. The purpose of the study was to evaluate the clinical significance of BBB disruption and the subsequent cerebrospinal fluid (CSF)/serum IgG gradient in NMO.
Background: Acute transverse myelitis (ATM) in patients with no history of central nervous system (CNS) demyelinating disease may be idiopathic or herald the development of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS). NMOSD may differ from MS in pathogenesis, prognosis and response to treatment, and radiological features at the first presentation of ATM that distinguish between NMOSD and MS would be desirable
BACKGROUND: Few data exist on a possible benign form of neuromyelitis optica (NMO). OBJECTIVES: To identify NMO with a good outcome (go-NMO) among a large population of patients and to describe demographic and clinical variables associated with go-NMO vs standard NMO and benign multiple sclerosis.
Neuromyelitis optica (NMO) is an uncommon idiopathic demyelinating disease of the central nervous system and is sometimes unresponsive to steroid treatment as compared to multiple sclerosis (MS). There are only a few reports of plasma exchange (PE) as an effective rescue treatment when high-dose steroid therapy fails in exacerbations of NMO.
OBJECTIVE. Our goal was to describe the spectrum of clinical phenotypes, laboratory and imaging features, and treatment in pediatric patients with neuromyelitis optica.PATIENTS AND METHODS
Background Neuromyelitis optica spectrum disorders (NMOSD) are severe central nervous system inflammatory demyelinating disorders (CNS IDD) characterized by monophasic or relapsing, longitudinally extensive transverse myelitis (LETM) and/or optic neuritis (ON). A significant proportion of NMOSD patients are seropositive for aquaporin-4 (AQP4) autoantibodies